arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

MAIA Biotechnology, Inc.

MAIA

$1.44 ▲ +0.02 (+1.41%) at close

20 Visible periods

21 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, MAIA Biotechnology, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $65.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -19.8% ↗

FCF / Share $-0.12

Trailing P/E —

Price / Book 3.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

20-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-6.37M

↓ -41.0% —

FCF / Share Free cash flow per share

$-0.12

↑ +22.6% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -1021.6% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.84x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗
EPS Growth YoY (%)	12.5% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	33.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-145.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	55.0% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	65.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	70.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	69.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-14.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-21.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-13.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	26.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	12.5% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	24.0% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	-16.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	52.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	48.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-41.0% Weak ↓ Weak Declining Year-over-year change in net income	-1.6% Weak ↓ Weak Declining Year-over-year change in net income	44.0% Excellent → Excellent Stable Year-over-year change in net income	44.0% Excellent ↑ Excellent Improving Year-over-year change in net income	44.0% Excellent ↑ Excellent Improving Year-over-year change in net income	—	-96.0% Weak → Weak Stable Year-over-year change in net income	-96.0% Weak ↓ Weak Declining Year-over-year change in net income	-96.0% Weak ↓ Weak Declining Year-over-year change in net income	—	-20.6% Weak ↑ Weak Improving Year-over-year change in net income	-24.5% Weak ↑ Weak Improving Year-over-year change in net income	-20.6% Weak ↑ Weak Improving Year-over-year change in net income	—	-123.8% Weak Weak Year-over-year change in net income	3.6% Caution Caution Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	22.6% Good Good Year-over-year change in free cash flow	—	—	—	25.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	33.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	15.5% Good Good Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗
FCF / Net Income (x)	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.93x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	0.44x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗
Return on Invested Capital (%)	-19.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-143.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17746.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-105.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	-108.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Return on Capital (%) (%)	-19.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-44.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-79.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-46.8% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-45.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-45.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-70.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-46.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-27.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-26.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-22.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-253%)	-152.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1118%)	—	-116.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-877%)	—	-98.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-755%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗
Interest Coverage (x)	—	—	—	—	—	—	-49276.09x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-4955643.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2719.91x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-812.95x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-815.04x Weak Weak Operating income divided by interest expense Optimal: > 5x	-2328.80x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-4.95x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—	$0.00	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗
Revenue per Share (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.14	$-0.08	$-0.27	$-0.18	$-0.16	$-0.12	$-0.11	$-0.40	$-0.46	$-0.41	$-0.36	$-0.35	$-0.38	$-0.36	$-0.49	$-0.40	$-0.50	$-0.31	$-1.02	$-0.78
Free Cash Flow per Share (USD)	$-0.12	—	$-0.11	$-0.14	$-0.15	—	—	—	$-0.20	—	—	—	$-0.31	—	—	—	$-0.36	—	$-0.26	—
Book Value per Share (USD)	$0.46	$0.06	$0.00	$0.12	—	$0.14	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$0.46	$0.06	$0.00	$0.12	—	$0.14	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	45.21M	—	33.20M	30.30M	27.70M	—	23.89M	22.20M	17.60M	—	13.68M	12.89M	10.98M	—	10.17M	8.20M	7.75M	—	5.12M	4.37M

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗
Working Capital (USD)	$28.99M	$3.87M	$1.76M	$6.00M	$6.80M	$6.32M	$5.63M	$8.51M	$3.79M	$2.63M	$2.48M	$6.50M	$4.57M	$8.54M	$12.32M	$5.51M	—	$8.53M	—	—
LT Debt (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$0.00	—	—	—	—
Total Equity (USD)	$27.76M	$2.38M	$41.67K	$3.88M	—	$3.63M	—	—	—	—	—	—	—	—	—	—	—	—	—	—

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$0.00	—	—	—	—	—
Net Income, GAAP (USD)	$-6.37M	$-3.63M	$-4.52M	$-4.52M	$-4.52M	$-3.57M	$-8.07M	$-8.07M	$-8.07M	—	$-4.12M	$-4.12M	$-4.12M	—	$-3.41M	$-3.31M	$-3.41M	—	$-1.53M	$-3.43M
Operating Cash Flow (USD)	$-5.31M	$-7.02M	$-3.49M	$-4.14M	$-4.20M	$-3.91M	—	—	$-3.59M	$-3.99M	—	—	$-3.36M	$-2.95M	—	—	$-2.81M	$-1.61M	$-1.31M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 20 quarters

MAIA Biotechnology, Inc.

Analytical Summary

20-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare MAIA with peers